id: NEW:sglt2_inhibitor_formulary_coverage_to_end_stage_renal_disease_incidence
name: SGLT2 Inhibitor Formulary Coverage â†’ End-Stage Renal Disease Incidence
from_node:
  node_id: NEW:sglt2_inhibitor_formulary_coverage
  node_name: SGLT2 Inhibitor Formulary Coverage
to_node:
  node_id: end_stage_renal_disease_incidence
  node_name: End-Stage Renal Disease Incidence
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Health systems include SGLT2 inhibitors in standard formularies for CKD treatment'
- 'Step 2: Cost-effectiveness evidence supports payer coverage decisions'
- 'Step 3: Patients receive SGLT2 inhibitors as part of standard care protocols'
- 'Step 4: Treatment slows GFR decline and reduces proteinuria'
- 'Step 5: Fewer patients progress to dialysis-dependent end-stage renal disease'
evidence:
  quality_rating: A
  n_studies: 13
  primary_citation: 'Anh Thi Ngoc Toan et al. 2024. "Cost-effectiveness of sodium-glucose cotransporter
    2 inhibitors in the treatment of chronic kidney disease: a systematic review." https://doi.org/10.1080/14737167.2024.2420654'
  supporting_citations:
  - Model-based cost-utility studies evaluating Empagliflozin (n=3)
  - Model-based cost-utility studies evaluating Canagliflozin (n=3)
  - Model-based cost-utility studies evaluating Dapagliflozin (n=8)
  doi: 10.1080/14737167.2024.2420654
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Health system adoption of SGLT2 inhibitors as cost-effective or cost-saving treatment options
  influences population-level progression to end-stage renal disease by enabling broader access to nephroprotective
  therapies.
spatial_variation:
  varies_by_geography: true
  variation_notes: Economic evaluations were conducted across multiple countries with varying healthcare
    systems and cost structures
moderators:
- name: health_system_perspective
  direction: strengthens
  strength: strong
  description: When analyzed from health system perspective in high-income countries, SGLT2 inhibitors
    with SoC were cost-saving for CKD patients with T2D
structural_competency:
  equity_implications: This mechanism addresses structural healthcare policy decisions that determine
    medication access. Cost-effectiveness evidence influences formulary decisions, which in turn affect
    population health outcomes. Disparities in healthcare infrastructure, insurance coverage, and pharmaceutical
    pricing policies create inequitable access to these treatments across and within countries. The economic
    burden of CKD disproportionately affects lower-income populations who may face greater barriers to
    accessing optimal treatment.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:36.926965'
  extraction_confidence: medium
  prompt_version: 2.1-canonical-validated
